Browsing by Author "Le Corre, Nicole "
Now showing 1 - 8 of 8
Results Per Page
Sort Options
- ItemAutoantibodies against type I IFNs in patients with critical influenza pneumonia(2022) Zhang, Qian; Pizzorno, Andres; Miorin, Lisa; Bastard, Paul; Gervais, Adrian; Le Voyer, Tom; Bizien, Lucy; Manry, Jeremy; Rosain, Jeremie; Philippot, Quentin; Goavec, Kelian; Padey, Blandine; Cupic, Anastasija; Laurent, Emilie; Saker, Kahina; Vanker, Martti; Saerekannu, Karita; Garcia-Salum, Tamara; Ferres, Marcela; Le Corre, Nicole; Sanchez-Cespedes, Javier; Balsera-Manzanero, Maria; Carratala, Jordi; Retamar-Gentil, Pilar; Abelenda-Alonso, Gabriela; Valiente, Adoracion; Tiberghien, Pierre; Zins, Marie; Debette, Stephanie; Meyts, Isabelle; Haerynck, Filomeen; Castagnoli, Riccardo; Notarangelo, Luigi D.; Gonzalez-Granado, Luis I.; Dominguez-Pinilla, Nerea; Andreakos, Evangelos; Triantafyllia, Vasiliki; Rodriguez-Gallego, Carlos; Sole-Violan, Jordi; Ruiz-Hernandez, Jose Juan; Rodriguez de Castro, Felipe; Ferreres, Jose; Briones, Marisa; Wauters, Joost; Vanderbeke, Lore; Feys, Simon; Kuo, Chen-Yen; Lei, Wei-Te; Ku, Cheng-Lung; Tal, Galit; Etzioni, Amos; Hanna, Suhair; Fournet, Thomas; Casalegno, Jean-Sebastien; Queromes, Gregory; Argaud, Laurent; Javouhey, Etienne; Rosa-Calatrava, Manuel; Cordero, Elisa; Aydillo, Teresa; Medina, Rafael A.; Kisand, Kai; Puel, Anne; Jouanguy, Emmanuelle; Abel, Laurent; Cobat, Aurelie; Trouillet-Assant, Sophie; Garcia-Sastre, Adolfo; Casanova, Jean-LaurentIn an international cohort of 279 patients with hypoxemic influenza pneumonia, we identified 13 patients (4.6%) with autoantibodies neutralizing IFN-alpha and/or -omega, which were previously reported to underlie 15% cases of life-threatening COVID-19 pneumonia and one third of severe adverse reactions to live-attenuated yellow fever vaccine.
- ItemCharacterization of Oral Immunity in Cases and Close Household Contacts Exposed to Andes Orthohantavirus (ANDV)(2020) Martinez-Valdebenito, Constanza; Andaur, Camila; Angulo, Jenniffer; Henriquez, Carolina; Ferres, Marcela; Le Corre, NicoleBackground: Andes orthohantavirus (ANDV) is the sole etiologic agent of Hantavirus Cardiopulmonary Syndrome in Chile and, until now, the only Hantavirus known to be transmitted by person-to-person route. The main risk of person-to-person transmission is to be a sexual partner of an index case, and deep kissing the main mechanism of infection. Experimental reports suggest that ANDV infection can be inhibited by some saliva components. Therefore, some host factors like saliva quality, could help to explain why some individuals do not become infected even though their exposure to the virus is high.
- ItemDifferent Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile(2023) Le Corre, Nicole; Abarca Villaseca, Katia; Astudillo, Patricio André; Potin Santander, Marcela Patricia; López, Sofía; Goldsack, Macarena; Valenzuela Guerrero, Vania; Schilling Redlich, Andrea; Gaete, Victoria; Rubio, Lilian; Calvo, Mario; Twele, Loreto; González, Marcela; Fuentes, Daniela; Gutiérrez Muñoz, Valentina José; Reyes Zaldivar, Felipe Tomás; Tapia, Lorena I.; Villena, Rodolfo; Retamal Díaz, Angello; Cárdenas, Antonio; Alarcón Bustamante, Eduardo; Xin, Qianqian; González Aramundiz, José Vicente; Álvarez Figueroa, María Javiera; González Muñoz, Pablo Alberto; Bueno Ramírez, Susan; Soto Ramírez, Jorge Andrés; Perret Pérez, Cecilia; Meng, Xing; Kalergis Parra, Alexis MikesDuring the COVID-19 pandemic, the importance of vaccinating children against SARS-CoV-2 was rapidly established. This study describes the safety of CoronaVac® in children and adolescents between 3- and 17-years-old in a multicenter study in Chile with two vaccine doses in a 4-week interval. For all participants, immediate adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs) were registered throughout the study. In the safety subgroup, AEs were recorded 28 days after each dose. COVID-19 surveillance was performed throughout the study. A total of 1139 individuals received the first and 1102 the second dose of CoronaVac®; 835 were in the safety subgroup. The first dose showed the highest number of AEs: up to 22.2% of participants reported any local and 17.1% systemic AE. AEs were more frequent in adolescents after the first dose, were transient, and mainly mild. Pain at the inoculation site was the most frequent AE for all ages. Fever was the most frequent systemic AE for 3–5 years old and headache in 6–17 years old. No SAEs or AESIs related to vaccination occurred. Most of the COVID-19 cases were mild and managed as outpatients. CoronaVac® was safe and well tolerated in children and adolescents, with different safety patterns according to age.
- ItemDifferential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile(2022) Acevedo, Monica L.; Gaete-Argel, Aracelly; Alonso-Palomares, Luis; de Oca, Marco Montes; Bustamante, Andres; Gaggero, Aldo; Paredes, Fabio; Cortes, Claudia P.; Pantano, Sergio; Martinez-Valdebenito, Constanza; Angulo, Jenniffer; Le Corre, Nicole; Ferres, Marcela; Navarrete, Marcelo A.; Valiente-Echeverria, Fernando; Soto-Rifo, RicardoThe SARS-CoV-2 Lambda variant has been prevalent in Latin America. An analysis of the neutralization capacity of antibodies elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in plasma from healthcare workers and patients in Chile reveals that BNT162b2 elicits higher neutralizing antibody titres than CoronaVac.
- ItemEarly Anti-SARS-CoV-2 Convalescent Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial(2020) Balcells, María Elvira ; Rojas, Luis ; Le Corre, Nicole ; Martínez-Valdebenito, Constanza ; Ceballos, María Elena ; Ferrés, Marcela ; Chang, Mayling ; Vizcaya, Cecilia ; Mondaca, Sebastián ; Huete, Álvaro ; Castro, Ricardo ; Sarmiento, Mauricio ; Villarroel, Luis ; Pizarro, Alejandra; Ross, Patricio ; Santander, Jaime ; Lara, Barbara ; Ferrada, Marcela ; Vargas-Salas, Sergio ; Beltrán-Pavez, Carolina ; Soto-Rifo, Ricardo ; Valiente-Echeverría, Fernando ; Caglevic, Christian ; Mahave, Mauricio ; Selman, Carolina ; Gazitúa, Raimundo ; Briones, José Luis ; Villarroel-Espindola, Franz ; Balmaceda, Carlos ; Espinoza, Manuel A. ; Pereira, Jaime ; Nervi, Bruno
- ItemKinetic of humoral response induced by SARS-CoV-2 infection in convalescent plasma receptors and donors(WILEY, 2021) Barrera, Aldo; Martinez Valdebenito, Constanza; Rojas Orellana, Luis; Vizcaya Altamirano, Cecilia; Elena Ceballos, Maria; Pereira, Jaime; Chang, Mayling; Mondaca, Sebastian; Sarmiento, Mauricio; Ross, Patricio; Henriquez, Carolina; Nervi, Bruno; Ferres, Marcela; Balcells, Elvira; Le Corre, Nicole
- ItemSARS-CoV-2 infectivity and antigenic evasion: spotlight on isolated Omicron sub-lineages(2024) Barrera, Aldo; Martinez-Valdebenito, Constanza; Angulo, Jenniffer; Palma, Carlos; Hormazabal, Juan; Vial, Cecilia; Aguilera, Ximena; Castillo-Torres, Pablo; Pardo-Roa, Catalina; Balcells, Maria Elvira; Nervi, Bruno; Le Corre, Nicole; Ferres, MarcelaSince the SARS-CoV-2 outbreak in 2019, a diversity of viral genomic variants has emerged and spread globally due to increased transmissibility, pathogenicity, and immune evasion. By the first trimester of 2023 in Chile, as in most countries, BQ and XBB were the predominant circulating sub-lineages of Omicron. The molecular and antigenic characteristics of these variants have been mainly determined using non-authentic spike pseudoviruses, which is often described as a limitation. Additionally, few comparative studies using isolates from recent Omicron sub-lineages have been conducted. In this study, we isolated SARS-CoV-2 variants from clinical samples, including the ancestral B.1.1, Delta, Omicron BA.1, and sub-lineages of BA.2 and BA.5. We assessed their infectivity through cell culture infections and their antibody evasion using neutralization assays. We observed variations in viral plaque size, cell morphology, and cytotoxicity upon infection in Vero E6-TMPRSS2 cells for each variant compared to the ancestral B.1.1 virus. BA.2-derived sub-variants, such as XBB.1.5, showed attenuated viral replication, while BA.5-derived variants, such as BQ.1.1, exhibited replication rates similar to the ancestral SARS-CoV-2 virus. Similar trends were observed in intestinal Caco-2 cells, except for Delta. Antibody neutralization experiments using sera from individuals infected during the first COVID-19 wave (FWI) showed a consistent but moderate reduction in neutralization against Omicron sub-lineages. Interestingly, despite being less prevalent, BQ.1.1 showed a 6.1-fold greater escape from neutralization than XBB.1.5. Neutralization patterns were similar when tested against sera from individuals vaccinated with 3xBNT162b2 (PPP) or Coronavac-Coronavac-BNT162b2 (CCP) schedules. However, CCP sera showed 2.3-fold higher neutralization against XBB.1.5 than FWI and PPP sera. This study provides new insights into the differences between BA.2 and BA.5-derived variants, leading to their eventual outcompetition. Our analysis offers important evidence regarding the balance between infectivity and antigenic escape that drives the evolution of second-generation SARS-CoV-2 variants in the population.
- ItemViral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study(2024) Ferres, Marcela; Martinez-Valdebenito, Constanza; Henriquez, Carolina; Marco, Claudia; Angulo, Jenniffer; Barrera, Aldo; Palma, Carlos; Pinto, Gonzalo Barriga; Cuiza, Analia; Ferreira, Leonila; Rioseco, Maria Luisa; Calvo, Mario; Fritz, Ricardo; Bravo, Sebastian; Bruhn, Alejandro; Graf, Jeronimo; Llancaqueo, Alvaro; Rivera, Gonzalo; Cerda, Carolina; Tischler, Nicole; Valdivieso, Francisca; Vial, Pablo; Mertz, Gregory; Vial, Cecilia; Le Corre, NicoleBackground Andes virus (ANDV) is a zoonotic Orthohantavirus leading to hantavirus cardiopulmonary syndrome. Although most transmissions occur through environmental exposure to rodent faeces and urine, rare person -toperson transmission has been documented, mainly for close contacts. This study investigates the presence and infectivity of ANDV in body fluids from confirmed cases and the duration of viraemia. Methods In this prospective study, 131 participants with confirmed ANDV infection were enrolled in Chile in a prospective study between 2008 and 2022. Clinical samples (buffy coat, plasma, gingival crevicular fluid [GCF], saliva, nasopharyngeal swabs [NPS], and urine) were collected weekly for 3 weeks together with clinical and epidemiological data. Samples were categorised as acute or convalescent (up to and after 16 days following onset of symptoms). Infectivity of positive fluids was assessed after the culture of samples on Vero E6 cells and use of flow cytometry assays to determine the production of ANDV nucleoprotein. Findings ANDV RNA was detected in 100% of buffy coats during acute phase, declining to 95% by day 17, and to 93% between days 23-29. ANDV RNA in GCF and saliva decreased from 30% and 12%, respectively, during the acute phase, to 12% and 11% during the convalescent phase. Successful infectivity assays of RT-qPCR-positive fluids, including GCF, saliva, NPS, and urine, were observed in 18 (42%) of 43 samples obtained during the acute phase of infection. After re -culture, the capacity to infect Vero E6 cells was maintained in 16 (89%) of 18 samples. Severity was associated with the presence of ANDV RNA in one or more fluids besides blood (odds ratio 258 [95% CI 142-518]). Interpretation ANDV infection is a systemic and viraemic infection, that affects various organs. The presence of infectious particles in body fluids contributes to our understanding of potential mechanisms for person -to -person transmission, supporting the development of preventive strategies. Detection of ANDV RNA in additional fluids at hospital admission is a predictor of disease severity. Funding National Institutes of Health and Agencia de Investigaci & oacute;n y Desarrollo. Copyright (c) 2024 Elsevier Ltd. All rights reserved.